atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects fo...
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovativ...
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to deli...
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at . A rebroadcast of the ...
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the followin...
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the Worl...
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant...
Four Directors at Blackrock Inc gave away/sold/sold after exercising options 49,442 shares at between 0.000USD and 1,125.599USD. The significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
BlackRock® Canada Announces Final July Cash Distributions for the iShares® Premium Money Market ETF TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final July 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on July 28, 2025, will receive cash distributions payable on July 31, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund Ticker Cash Distributi...
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpointInidascamine continues to exhibit a favorable safety and tolerability profileFull data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognif...
BlackRock® Canada Announces July Cash Distributions for the iShares® ETFs TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the July 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly basis. Unitholders of record of the applicable iShares ETF on July 28, 2025 will receive cash distributions payable in respect of that iShares ETF on July 31, 2025. Details regarding the “per unit” distribution amoun...
atai Life Sciences Announces $50 Million Private Placement Financing Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary...
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of trea...
BlackRock® Canada Announces Final June Cash Distributions for the iShares® Premium Money Market ETF TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final June 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on June 25, 2025 will receive cash distributions payable on June 30, 2025. Details regarding the final “per unit” distribution amounts are as follows: Fund NameFund Ticker Cash Distribution Per Unit iSha...
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation’s request for a preli...
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE, Tenn., June 23, 20...
BlackRock® Canada Announces June Cash Distributions for the iShares® ETFs TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the June 2025 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly, quarterly, or semi-annual basis. Unitholders of record of the applicable iShares ETF on June 25, 2025 will receive cash distributions payable in respect of that iShares ETF on June 30, 2025. Details regarding the “per...
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has anno...
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today anno...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.